Merck & Co., Inc. (MRK) vs Roche Holding AG (RO.SW)

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.

Roche Holding AG is a publicly traded company. It is a Swiss healthcare company focused on pharmaceuticals and diagnostics, including oncology, immunology, neuroscience, infectious disease, and laboratory testing. The company's performance is influenced by revenue growth, margins, capital allocation, competitive positioning, regulation, currency movements where relevant, and broader economic and market conditions affecting its industry.